Another alliance of health care and AI signals why pharma stocks should be back in favor
Bristol Myers Squibb and Microsoft's new partnership aimed at accelerating early detection of lung cancer.
TL;DR
- Bristol Myers Squibb and Microsoft are collaborating on an AI-powered radiology platform to improve early lung cancer detection.
- Eli Lilly and Nvidia are jointly investing up to $1 billion over five years in an AI-focused innovation lab for drug discovery.
- The article suggests a shift in investor focus from AI to healthcare stocks, driven by a more inviting deal environment.
- Bristol Myers' stock performance is linked to trial results for its drug Cobenfy.
- Jim Cramer is considering swapping the Charitable Trust's position in Bristol Myers for other pharma or biotech names.